RT Journal Article
SR Electronic
T1 Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005871
DO 10.1136/jitc-2022-005871
VO 11
IS 1
A1 Marquardt, Viktoria
A1 Theruvath, Johanna
A1 Pauck, David
A1 Picard, Daniel
A1 Qin, Nan
A1 Blümel, Lena
A1 Maue, Mara
A1 Bartl, Jasmin
A1 Ahmadov, Ulvi
A1 Langini, Maike
A1 Meyer, Frauke-Dorothee
A1 Cole, Allison
A1 Cruz-Cruz, Joselyn
A1 Graef, Claus M
A1 Wölfl, Matthias
A1 Milde, Till
A1 Witt, Olaf
A1 Erdreich-Epstein, Anat
A1 Leprivier, Gabriel
A1 Kahlert, Ulf
A1 Stefanski, Anja
A1 Stühler, Kai
A1 Keir, Stephen T
A1 Bigner, Darell D
A1 Hauer, Julia
A1 Beez, Thomas
A1 Knobbe-Thomsen, Christiane B
A1 Fischer, Ute
A1 Felsberg, Jörg
A1 Hansen, Finn K
A1 Vibhakar, Rajeev
A1 Venkatraman, Sujatha
A1 Cheshier, Samuel H
A1 Reifenberger, Guido
A1 Borkhardt, Arndt
A1 Kurz, Thomas
A1 Remke, Marc
A1 Mitra, Siddhartha
YR 2023
UL http://jitc.bmj.com/content/11/1/e005871.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.